cropper

The Silver Surfer
Senior Citizens Surfing the Internet

  • Home
  • Categories
    • Health & Wellness
    • Money & Legal
    • Housing & Living
    • Lifestyle & Leisure
    • Technology for Seniors
    • Local Resources
January 05.2026
2 Minutes Read

Breaking New Ground: Is CAR T-Cell Therapy the Cure for Myeloma or Just a Step Forward?

3D illustration of myeloma cells interaction, Cure for Myeloma.

Understanding CAR T-Cell Therapy: The Hope for Myeloma Patients

Chimeric antigen receptor T-cell (CAR T-cell) therapy represents a monumental advancement in cancer treatment, particularly for patients suffering from relapsed and refractory multiple myeloma. This innovative therapy uses modified T-cells from a patient's body to specifically target cancer cells, showcasing superior outcomes compared to previous treatment options.

Update on Recent Research Findings

Recent findings from the CARTITUDE-1 trial have generated significant excitement in the oncology community. In a cohort of heavily pretreated patients, nearly half achieved substantial long-term survival—showing a median overall survival (OS) of 60.7 months. Remarkably, approximately 75% of these patients remained free of disease progression. Such outcomes, as noted by researchers, suggest an unprecedented durability of response to cilta-cel, opening discussions around the possibility of a functional cure.

During the American Society of Clinical Oncology (ASCO) Conference, experts highlighted these emerging results, with Dr. Sundar Jagannath asserting it's time to embrace the notion of a 'cure' in multiple myeloma treatment, especially as patients bask in renewed hope. These sentiments mark a pivotal shift in acceptance among hematologists about disease treatment trajectories.

The Debate: What Constitutes a Cure?

Nevertheless, the definition of what constitutes a 'cure' remains contentious. Dr. Jagannath suggests employing minimal residual disease (MRD) as a benchmark for curing myeloma, encouraging researchers and practitioners alike to shift away from medical jargon that implies a less favorable prognosis. Contrarily, some practitioners argue that focusing strictly on MRD may inadvertently lead to overtreatment, especially considering the inherent risks associated with aggressive therapies.

Long-Term Outcomes and Quality of Life

For many patients, achieving a long-term survival with a reasonable quality of life remains paramount. While some experts like Dr. James Berenson caution against overly aggressive treatment paradigms—considering the financial burden of therapies that can soar to over a million dollars a year—it’s essential to balance therapeutic intent with patients’ life experiences. The valuable insight here is that for many patients, a good quality of life can outweigh the pursuit of a stringent curative benchmark.

Future Trends: Enhancing Treatment Approaches

As CAR T-cell therapies advance, ongoing research aims to refine these treatment techniques further. Trials such as CARTITUDE-6 are set to compare CAR T-cell therapy directly against traditional autologous stem cell transplantation in newly diagnosed patients, aiming to elucidate the safety and efficacy of both approaches.

Moreover, the pursuit of novel therapies targeting other antigens, like GPRC5D, could revolutionize treatment modalities, offering new hope for patients with resistant myeloma. With continued innovation and research tailored towards improving patient outcomes, the future of multiple myeloma treatment is bright.

Conclusion: The Path Ahead

The ongoing discussions and emerging data reaffirm the need for a multifaceted approach to treating multiple myeloma today. As we navigate this evolving landscape, one fact remains clear: the exploration of what a 'cure' truly means will continue to define the hopeful journey for myeloma patients and their families.

Health & Wellness

20 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
11.19.2026

Breakthrough Insights: Diranersen Therapy Shows Benefits for Alzheimer's Patients Over Two Years

Update Understanding Tau Therapy's Promising Benefits for Alzheimer's Patients In a remarkable breakthrough for Alzheimer's research, diranersen, an investigational medication, continues to show significant benefits in slowing the decline of cognitive abilities. Recent findings from a two-year study confirm that this therapy works by targeting tau protein, a key factor in the progression of Alzheimer's disease. Presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference, Dr. Lawren VandeVrede from the University of California San Francisco highlighted that over 96 weeks, diranersen led to a meaningful recovery in cognitive functions. How Diranersen Works and Its Impact on Cognitive Decline Diranersen is an antisense oligonucleotide therapy that aims to reduce tau levels, which can collect in the brain and contribute to the disease's progression. The results showed a 1.09-point improvement in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score among participants who received a 60-mg dose twice a year. This dosage displayed the most significant results, proving invaluable since a one-point change in CDR-SB is considered clinically meaningful. A Closer Look at the Study and Its Findings The CELIA trial enrolled 416 participants with mild cognitive impairment from Alzheimer's disease and tested different doses of diranersen. Interestingly, while various dosages were evaluated, the lower 60-mg dose performed the best, leading to a 38% improvement in cognitive measures between 76 and 96 weeks. As the findings continue to evolve, researchers are optimistic about this therapy's potential to enhance cognitive function for a longer duration, which could mean new hope for patients struggling with this debilitating disease. Safety and Future Implications of Diranersen While the results are promising, it is important to consider the safety profile. During the study, adverse events were common but mostly mild, such as headaches and post-lumbar puncture syndrome. These findings continuously reassure researchers about the therapy's tolerability. Experts emphasize that diranersen's ability to lower tau without affecting amyloid protein makes it particularly exciting. This presents a potential strategy in combined therapies that target multiple aspects of Alzheimer's, aiming for a more comprehensive approach to treatment. Looking Ahead: The Future of Alzheimer's Treatments The upcoming phase III trials will be crucial in confirming the effectiveness and safety of diranersen on a larger scale. As Laura Nisenbaum, interim chief science officer of the Alzheimer's Drug Discovery Foundation, points out, understanding how tau therapy can work alongside traditional anti-amyloid treatments could be groundbreaking in the fight against Alzheimer's disease. As Alzheimer's affects millions, continued research like this offers hope and insight into managing and potentially reversing symptoms. Stay informed about these developments as they may mark a new era in Alzheimer's treatment that could benefit not just today’s patients but future generations.

11.18.2026

Why High Cardiac Troponin I Readings Alone Aren't Enough

Update Understanding Cardiac Troponins: The Basics Cardiac troponins, particularly troponin I (cTnI), are essential blood markers that help doctors understand heart health. These proteins are released when the heart is damaged, and measuring their levels can help indicate the risk of cardiovascular problems. However, recent research warns that simply looking at cTnI levels might not give the whole picture. What Are Macrotroponins and Why Do They Matter? Macrotroponins are complex molecules formed from autoantibodies attaching to troponin. They are much larger than regular troponins and can linger in the bloodstream longer, making tests show heightened cTnI levels. In simple terms, while doctors often look at high cTnI levels to assess heart health, they must also consider if these high levels are due to macrotroponins. New Findings from Norway: A Wake-Up Call In a significant study from Norway involving over 3,700 community members, researchers discovered some surprising truths. Those with high cTnI readings and no macrotroponins faced a staggering 50% chance of developing cardiovascular problems over 8.3 years. In contrast, those with high cTnI but also possessing macrotroponins had a much lower incident rate of just 6.8%. Why Misclassifying Risks Can Be Dangerous This misclassification could lead to critical oversights in patient care. High cTnI readings can indicate severe risk, but if macrotroponins are present, the actual risk may be much lower. Thus, it’s imperative for physicians to consider both cTnI levels and the presence of macrotroponins to make informed medical decisions. The Need for Enhanced Diagnostic Practices The study emphasizes that by recognizing the influence of macrotroponins, healthcare providers can improve their assessments of cardiac risk. This means creating fresh guidelines that factor in both troponin levels and macrotroponin presence could be monumental in shaping more accurate health responses. Final Thoughts: What This Means for Patients For those monitoring heart health, these insights are crucial. Patients should be aware that high cTnI does not automatically signal danger, especially if macrotroponins are present. Engaging in discussions with healthcare providers about testing methods and what results actually indicate can empower patients to better understand their cardiovascular risks.

11.17.2026

The Hidden Dangers of Agent Orange: Linking Exposure to Parkinson's Disease

Update Understanding the Link Between Agent Orange and Parkinson’s Disease Recent research has unveiled significant findings regarding the health risks faced by Vietnam-era military veterans exposed to Agent Orange, a potent herbicide used during the Vietnam War. A study of over 4 million Veterans Affairs (VA) health records has established that these veterans are at a 57% higher risk of developing Parkinson's disease and other neurodegenerative disorders. This alarming statistic indicates that veterans were not just courageous soldiers but also faced long-term health consequences from their service. What Is Agent Orange? Agent Orange was a toxic herbicide extensively utilized by the U.S. military to clear vegetation and expose enemy positions. This chemical was not just an ordinary weedkiller; it was a mixture containing 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), along with TCDD, a highly toxic dioxin. Despite the phasing out of 2,4,5-T in the 1970s, the use of 2,4-D remains prevalent today across various sectors, including agriculture and landscaping, which raises critical public health questions. Health Impacts of Agent Orange on Veterans The study led by Dr. Gregory Scott and his team highlights that veterans who handled Agent Orange directly had even higher chances—up to twice as likely—of developing Parkinson’s disease and related conditions, including REM sleep behavior disorder. This reinforces the long-held suspicions of healthcare providers and the veterans themselves regarding the link between Agent Orange exposure and neurodegenerative diseases. Broader Implications Beyond Veterans Time and again, evidence suggests that the toxic effects of Agent Orange are not limited to veterans alone. People living near agricultural areas where 2,4-D is used—like farmers and groundskeepers—face similar risks. Notably, recent studies revealed that living close to golf courses is associated with a 126% increased risk of Parkinson's disease, illustrating how widespread this issue is beyond military circles. Why Does This Matter Now? As we continue to learn about the long-term consequences of Agent Orange exposure, it becomes increasingly clear that proactive measures should be taken to prevent future exposures to harmful herbicides and pesticides. Dr. Scott emphasizes the need for immediate action to comprehend and address the health risks associated with newer herbicides before they become entrenched in our understanding, just as Agent Orange was for veterans. Conclusion: A Call for Awareness The findings of this recent study are a wake-up call for not only veterans but for communities across the U.S. As the knowledge of dangerous chemicals continues to evolve, so too must our efforts to protect public health. Advocacy for research into environmental health effects and vigilant monitoring of agricultural chemicals are imperative to safeguard both current and future generations. Understanding these risks can lead to stronger policies protecting veterans and civilians alike.

Silver Surfer Media

A division of

Electronic Commerce Engineering Corporation

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

+19085200096

AVAILABLE FROM 9AM - 5PM

Monday ~ Friday

Green Township, New Jersey

 07860-5406

ABOUT US

The Sussex County Advisor is operated by synergetic.media a subsidiary of  Electronic Commerce Engineering Corporation, Green Township, NJ 07860-5406

© 2026 Electronic Commerce Engineering Corporation All Rights Reserved. 16 Wintermute Rd, Green Township, NJ 07860-5406 . Contact Us . Terms of Service . Privacy Policy

{"company":"Electronic Commerce Engineering Corporation","address":"16 Wintermute Rd","city":"Green Township","state":"NJ","zip":"07860-5406","email":"info@ecommerceengineering.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*